← brief for 2026-09-07 · Slowing decline

GLP-1 receptor agonists beyond glycemic control: integrated cardio-renal-metabolic protection across the cardiovascular kidney metabolic continuum.

Article No results yet Peer reviewed

Key takeaways

This is an overview article, not a new trial. It gathers the large heart and diabetes trials of GLP-1 drugs, the family that includes semaglutide, and argues they protect the heart and kidneys beyond just lowering blood sugar. It names trials such as LEADER and REWIND as the evidence behind that claim. No new data are reported here, so the actual numbers live in those original trials.

Who did this work

Elsayed A · Ayoub WJ · Elsayed N · Stephens J · Udongwo N · Elsayed Y · Ghali JK

Source

Article · PubMed, the drug frontier · 2026 Sep 7
https://pubmed.ncbi.nlm.nih.gov/42702727/